Spruce Biosciences Nears BLA Submission for MPS IIIB Therapy, Secures $50M Loan — Spruce Biosciences, Inc.

Event summary

Spruce Biosciences reported a net loss of $39.0M for 2025, down from $53.0M in 2024, with cash reserves of $48.9M as of December 31, 2025.
The company secured up to $50M in growth capital from Avenue Capital in January 2026, with an initial tranche of $15M fully funded.
Spruce appointed Dale Hooks as Chief Commercial Officer and added regulatory and clinical development expertise to its leadership team.
Positive Type B meetings with the FDA in February 2026 confirmed that integrated study data could support an accelerated approval for TA-ERT.
Long-term data of TA-ERT presented at the 22nd Annual WORLDSymposium™ showed potential as the first disease-modifying treatment for MPS IIIB.

The big picture

Spruce Biosciences is positioning itself for a potential commercial launch of its tralesinidase alfa enzyme replacement therapy (TA-ERT) for MPS IIIB, a rare neurological disorder with no approved therapies. The company's strategic moves, including securing growth capital and strengthening its leadership team, reflect its commitment to capitalizing on the next phase of growth. The biopharmaceutical industry continues to focus on developing therapies for rare diseases, driven by regulatory incentives and the unmet medical needs of patients.

What we're watching

Regulatory Approval: Whether the FDA will grant accelerated approval for TA-ERT based on the existing clinical data and natural history data.
Commercial Launch: The pace at which Spruce Biosciences can build its commercial infrastructure and launch TA-ERT for MPS IIIB.
Financial Sustainability: How long the company's current cash reserves and loan facility will support its operating plan beyond the anticipated BLA submission.